Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 4/20 | 0.43 |
| ▸ | IL6ST | P40189 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 8/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17222138 | 1.00 | PPARA (0.43) | PPARAIL6STNAAAFAAHIDH1 | |
| SCHEMBL17222139 | 1.00 | PPARA (0.43) | PPARAIL6STNAAAFAAHIDH1 | |
| SCHEMBL17242161 | 0.91 | PPARA (0.42) | PPARAIL6STNAAAFAAHIDH1 | |
| SCHEMBL17242264 | 0.91 | PPARA (0.42) | PPARAIL6STNAAAFAAHIDH1 | |
| SCHEMBL17222038 | 0.90 | PPARA (0.41) | PPARAIL6STNAAAFAAHIDH1 | |
| SCHEMBL17221991 | 0.90 | PPARA (0.43) | PPARAIL6STNAAAFAAHIDH1 | |
| SCHEMBL13316603 | 0.90 | PPARA (0.43) | PPARAIL6STNAAAFAAHIDH1 | |
| SCHEMBL8274816 | 0.88 | PPARA (0.40) | PPARAIL6STNAAAFAAHIDH1 | |
| SCHEMBL17241959 | 0.88 | PPARA (0.40) | PPARAIL6STNAAAFAAHIDH1 | |
| SCHEMBL17222036 | 0.88 | PPARA (0.40) | PPARAIL6STNAAAFAAHIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802125-B2 | Functionalized heterocyclic compounds as antiviral agents | ENANTA PHARMACEUTICALS, INC. | 2023-10-31 | — | — | US | disclosed |
| WO-2021188414-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-20210292320-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2021-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292320-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS | HAVCR2, HDGF, HCCS | PPARA 1829/4885IL6ST 795/4885NAAA 3516/4885 |
| US-11802125-B2 | Functionalized heterocyclic compounds as antiviral agents | HAVCR2, HDGF, HCCS | PPARA 1829/4885IL6ST 795/4885NAAA 3516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.